Key Highlights

  • Surgery Partners (NASDAQ:SGRY) jumped about 14% on November 9, 2026, closing near USD 25.98, after its agreed buyer raised its offer amid a rival approach.
  • HealthSpan, an affiliate of Bon Secours Mercy Health, raised its cash offer to USD 25.00 per share from USD 23.50, valuing the deal at up to about USD 6 billion.
  • A ticking fee could add up to USD 1.61 per share if closing is delayed, for maximum consideration of USD 26.61 per share.
  • An unnamed third party had proposed USD 28.00 per share in cash, but the special committee concluded it was not a superior proposal.

The Revised Agreement

Surgery Partners (NASDAQ:SGRY) operates more than 200 surgical facilities in 30 states, mainly ambulatory surgery centres that perform outpatient procedures at lower cost than hospitals. On October 26, 2026 it agreed to be acquired by HealthSpan for USD 23.50 per share, an Enterprise value of about USD 5.7 billion. The amended agreement announced on November 9 raises the price to USD 25.00, about 6.4% higher. It also adds a ticking fee: if shareholders approve the deal before March 1, 2027 but it has not closed, holders receive monthly payments at a 10% annual rate on USD 25.00, worth up to USD 1.61 per share if closing slips to the outside date of October 23, 2027. The largest shareholder, which owns about 39%, has agreed to vote in favour and will roll its stake into the new company rather than take cash, remaining a significant partner after the deal.

Why the Board Rejected USD 28

The rival approach, received on November 3 and updated on November 8, offered USD 28.00 in cash, about 12% above the revised price. The special committee, advised independently, unanimously concluded it was not a superior proposal. Its reasons were a longer and less certain path to closing, greater Regulatory Risk and weaker contractual protections. The board reaffirmed its recommendation for the HealthSpan deal, which management describes as offering regulatory certainty and a near-term close, expected in the first quarter of 2027. Financing comes from cash on hand and committed new debt. The market's reaction tells its own story. Shares closed near USD 25.98, above the agreed price, which suggests that some investors expect the bidding to continue or the rival to return with firmer terms.

Risks for Shareholders

Trading above the Offer Price carries risk. If the rival does not improve or firm up its proposal, holders of Surgery Partners (NASDAQ:SGRY) who bought near USD 26 would receive USD 25.00 plus any ticking fee, a modest loss before fees unless closing is delayed. The vote is also heavily influenced by the 39% holder, which supports the current deal. Regulatory review of healthcare transactions has tightened, and a lengthy process would trigger ticking fees but also delay cash. On the other hand, a firm and fully financed rival offer could force the board to reconsider. Investors will watch for any revised rival bid, the timing of the Shareholder vote and regulatory filings over the coming months. Shareholders should also consider whether the tax treatment and timing of the cash suit their own situation.

Where Things Stand

Surgery Partners jumped about 14% on November 9, 2026 after HealthSpan raised its offer to USD 25.00 per share, with a ticking fee of up to USD 1.61, while the board rejected a rival USD 28.00 proposal as not superior. Shares closing near USD 25.98 signal hopes for a higher bid. The rival's next move, the vote and regulatory approvals will decide the final outcome.